Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6 | Zendy

Nina Kerres | Zendy; Steffen Steurer | Zendy; Stefanie Schlager | Zendy; Gerd Bader | Zendy; Helmut Berger | Zendy; Maureen Caligiuri | Zendy; Christian Dank | Zendy; John R. Engen | Zendy; Peter Ettmayer | Zendy; Bernhard Fischerauer | Zendy; Gerlinde Flotzinger | Zendy; Daniel Gerlach | Zendy; Thomas Gerstberger | Zendy; Teresa Gmaschitz | Zendy; Peter Greb | Zendy; Bingsong Han | Zendy; Elizabeth Heyes | Zendy; Roxana E. Iacob | Zendy; Dirk Kessler | Zendy; Heike Kölle | Zendy; Lyne Lamarre | Zendy; David R. Lancia | Zendy; Simon Lucas | Zendy; Moriz Mayer | Zendy; Katharina Mayr | Zendy; Nikolai Mischerikow | Zendy; Katja Mück | Zendy; Christoph Peinsipp | Zendy; Oliver Petermann | Zendy; Ulrich Reiser | Zendy; Dorothea Rudolph | Zendy; Klaus Rumpel | Zendy; Carina Salomon | Zendy; Dirk Scharn | Zendy; Renate Schnitzer | Zendy; Andreas Schrenk | Zendy; Norbert Schweifer | Zendy; Diane Thompson | Zendy; Elisabeth Traxler | Zendy; Roland Varecka | Zendy; Tilman Voss | Zendy; A. Weiss-Puxbaum | Zendy; Sandra Winkler | Zendy; Xiaozhang Zheng | Zendy; Andreas Zoephel | Zendy; Norbert Kraut | Zendy; Darryl B. McConnell | Zendy; Mark Pearson | Zendy; Manfred Koegl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

Author(s) -

Nina Kerres,

Steffen Steurer,

Stefanie Schlager,

Gerd Bader,

Helmut Berger,

Maureen Caligiuri,

Christian Dank,

John R. Engen,

Peter Ettmayer,

Bernhard Fischerauer,

Gerlinde Flotzinger,

Daniel Gerlach,

Thomas Gerstberger,

Teresa Gmaschitz,

Peter Greb,

Bingsong Han,

Elizabeth Heyes,

Roxana E. Iacob,

Dirk Kessler,

Heike Kölle,

Lyne Lamarre,

David R. Lancia,

Simon Lucas,

Moriz Mayer,

Katharina Mayr,

Nikolai Mischerikow,

Katja Mück,

Christoph Peinsipp,

Oliver Petermann,

Ulrich Reiser,

Dorothea Rudolph,

Klaus Rumpel,

Carina Salomon,

Dirk Scharn,

Renate Schnitzer,

Andreas Schrenk,

Norbert Schweifer,

Diane Thompson,

Elisabeth Traxler,

Roland Varecka,

Tilman Voss,

A. Weiss-Puxbaum,

Sandra Winkler,

Xiaozhang Zheng,

Andreas Zoephel,

Norbert Kraut,

Darryl B. McConnell,

Mark Pearson,

Manfred Koegl

Publication year - 2017

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2017.08.081

Subject(s) - bcl6 , druggability , transcription factor , repressor , cancer research , lymphoma , biology , carcinogenesis , ubiquitin , chemistry , gene , microbiology and biotechnology , genetics , b cell , immunology , antibody , germinal center

The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL). Disruption of its interaction with transcriptional repressors interferes with the oncogenic effects of BCL6. We used a structure-based drug design to develop highly potent compounds that block this interaction. A subset of these inhibitors also causes rapid ubiquitylation and degradation of BCL6 in cells. These compounds display significantly stronger induction of expression of BCL6-repressed genes and anti-proliferative effects than compounds that merely inhibit co-repressor interactions. This work establishes the BTB domain as a highly druggable structure, paving the way for the use of other members of this protein family as drug targets. The magnitude of effects elicited by this class of BCL6-degrading compounds exceeds that of our equipotent non-degrading inhibitors, suggesting opportunities for the development of BCL6-based lymphoma therapeutics

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research